Comprehensive Therapy

, Volume 33, Issue 1, pp 2–17 | Cite as

Evidence-based Treatment of Chronic Heart Failure

Original Article

The past two decades have seen a knowledge explosion in the field of cardiovascular diseases, in general, and in the understanding of chronic heart failure (HF) as a complex neurohumoral syndrome in particular. A new staging system for chronic HF has been developed within the last decade to facilitate the evidence-based prescription of medications and medical devices for each of its four stages. The burden of care for patients with chronic HF is substantially provided in primary care settings. Primary care physicians need to understand the underlying pathophysiology of chronic HF, the elements of its evaluation and treatment by stage, and when referral is necessary.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    American Heart Association. Heart disease and stroke statistics. 2005 update. Dallas, TX: American Heart Association; 2005.Google Scholar
  2. 2.
    Lee WC, Chavez YE, Baker T. Economic burden of heart failure: a summary of recent literature. Heart Lung 2005;33:362–71.CrossRefGoogle Scholar
  3. 3.
    American Heart Association. 2002 heart and stroke statistical update. Dallas, TX: American Heart Association; 2002.Google Scholar
  4. 4.
    Hunt SA, American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:e1–82.PubMedCrossRefGoogle Scholar
  5. 5.
    Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999;100:999–1008.PubMedGoogle Scholar
  6. 6.
    Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2004;289:194–202.CrossRefGoogle Scholar
  7. 7.
    Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 1998;97:282–9.PubMedGoogle Scholar
  8. 8.
    Burkhoff D, Maurer MS, Packer M. Heart failure with a normal ejection fraction: is it really a disorder of diastolic function? Circulation 2003;107:656–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Smith GL, Masoudi FA, Vaccarino V, Radford MJ, Krumholz HM. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol 2003;41:1510–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Tang WHW, Francis GS. The year in heart failure. J Am Coll Cardiol 2006;48:2575–83.PubMedCrossRefGoogle Scholar
  12. 12.
    Androne AS, Katz SD, Lund L, LaManca J, Hudaihed A, Hryniewicz K, et al. Hemodilution is common in patients with advanced heart failure. Circulation 2003;107:226–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206–52.PubMedCrossRefGoogle Scholar
  14. 14.
    Baker DW. Prevention of heart failure. J Card Fail 2002;8:333–46.PubMedCrossRefGoogle Scholar
  15. 15.
    Kostis JB, Davis BR, Cutler J, Grimm RH Jr, Berge KG, Cohen JD, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 1997;278:212–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145–53.PubMedCrossRefGoogle Scholar
  17. 17.
    Brauwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058–68.CrossRefGoogle Scholar
  18. 18.
    Harris EE, Correa C, Hwang WT, Liao J, Litt HI, Ferrari VA, Solin LJ. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast conservation treatment. J Clin Oncol 2006;24:4100–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Cardinale D, Colombbo, A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114:2474–81.PubMedCrossRefGoogle Scholar
  20. 20.
    Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–83.PubMedCrossRefGoogle Scholar
  21. 21.
    The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions (published erratum appears in N Engl J Med 1992;327:1768). N Engl J Med 1992:685–91.Google Scholar
  22. 22.
    Vantrimpont P, Rouleau JL, Wun CC, Ciampi A, Klein M, Sussex B, et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol 1997;29:229–36.PubMedCrossRefGoogle Scholar
  23. 23.
    Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement Trial. The SAVE Investigators. N Engl J Med 1992;327:669–77.PubMedCrossRefGoogle Scholar
  24. 24.
    Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801–7.Google Scholar
  25. 25.
    Bonow RO, Carabello B, de Leon AC Jr, Edmunds LH Jr, Fedderly BJ, Freed MD, et al. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease). Circulation 1998;98:1949–84.PubMedGoogle Scholar
  26. 26.
    Aronow, WS. Treatment of heart failure with a normal left ventricular ejection fraction in the elderly. Geriatrics 2006;61:16–20.PubMedGoogle Scholar
  27. 27.
    Granger BB, Swedberg K, Ekman I, Granger CB, Olofsson B, McMurray JJ, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 2005;366:2005–11.PubMedCrossRefGoogle Scholar
  28. 28.
    Wilson JR, Reichek N, Dunkman WB, Goldberg S. Effect of diuresis on the performance of the failing left ventricle in man. Am J Med 1981;70:234–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Cody RJ, Franklin KW, Laragh JH. Postural hypotension during tilt with chronic captopril and diuretic therapy of severe congestive heart failure. Am Heart J 1982;103:480–4.PubMedCrossRefGoogle Scholar
  30. 30.
    The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999;353:9–13.Google Scholar
  31. 31.
    Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283:1295–302.PubMedCrossRefGoogle Scholar
  32. 32.
    Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385–90.PubMedCrossRefGoogle Scholar
  34. 34.
    Chalmers JP, West MJ, Cyran J, De La Torre D, Englert M, Kramar M, et al. Placebo-controlled study of lisinopril in congestive heart failure: a multicentre study. J Cardiovasc Pharmacol 1987;9 Suppl 3:S89–97.PubMedCrossRefGoogle Scholar
  35. 35.
    Pflugfelder PW, Baird MG, Tonkon MJ, DiBianco R, Pitt B. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators. J Am Coll Cardiol 1993;22:1557–63.PubMedCrossRefGoogle Scholar
  36. 36.
    Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997;79:115–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Teo KK, Yusuf S, Pfeffer M, Torp-Pedersen C, Kober L, Hall A, et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002;360:1037–43.PubMedCrossRefGoogle Scholar
  38. 38.
    Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005;112:2426–35.PubMedCrossRefGoogle Scholar
  39. 39.
    Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312–8.PubMedGoogle Scholar
  40. 40.
    Linz W, Scholkens BA. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 1992;105:771–2.PubMedGoogle Scholar
  41. 41.
    Fuchs SA, Meyboom RHB, van Puijenbroek EP, Guchelaar HJ. Use of angiotensin receptor antagonists in patients with ACE inhibitor induced angioedema. Pharm World Sci 2004;26:191–2.PubMedCrossRefGoogle Scholar
  42. 42.
    Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang YT, et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002;40:970–5.PubMedCrossRefGoogle Scholar
  43. 43.
    McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767–71.PubMedCrossRefGoogle Scholar
  44. 44.
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–17.PubMedCrossRefGoogle Scholar
  45. 45.
    Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001;15:79–87.PubMedCrossRefGoogle Scholar
  46. 46.
    Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543–51.PubMedCrossRefGoogle Scholar
  47. 47.
    Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle MG. Sympathoinhibitory responses to digitalis glycosides in heart failure patients: direct evidence from sympathetic neural recordings. Circulation 1989;80:65–77.PubMedGoogle Scholar
  48. 48.
    The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525–33.CrossRefGoogle Scholar
  49. 49.
    Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002;347:1043–411.CrossRefGoogle Scholar
  50. 50.
    Adams KF Jr, Gheorghiade M, Uretsky BF, Patterson JH, Schwartz TA, Young JB. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol 2002;39:946–53.PubMedCrossRefGoogle Scholar
  51. 51.
    Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino R Jr, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049–57.PubMedCrossRefGoogle Scholar
  52. 52.
    Belardinelli R, Georgiou D, Cianci G, Purcaro A. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation 1999;99:1173–82.PubMedGoogle Scholar
  53. 53.
    Knight BP, Goyal R, Pelosi F, Flemming M, Horwood L, Morady F, et al. Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. J Am Coll Cardiol 1999;33:1964–70.PubMedCrossRefGoogle Scholar
  54. 54.
    Shamim W, Francis DP, Yousufuddin M, Varney S, Pieopli MF, Anker SD, et al. Intraventricular conduction delay: a prognostic marker in chronic heart failure. Int J Cardiol 1999;70:171–8.PubMedCrossRefGoogle Scholar
  55. 55.
    McAlister F, Ezekowitz J, Wiebe N, Rowe B, Spooner C, Crumley E, et al. Cardiac resynchronization therapy for congestive heart failure. Evid Rep Technol Assess (Summ) 2004;106:1–8 (Nov).Google Scholar
  56. 56.
    Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140–50.PubMedCrossRefGoogle Scholar
  57. 57.
    Waggoner AD, Rovner A, de las Fuentes L, Faddis MN, Gleva MJ, Sawhney N, et al. Clinical outcomes after cardiac resynchronization therapy: importance of left ventricular diastolic function and origin of heart failure. J Am Soc Echocardiogr 2006;19:307–13.PubMedCrossRefGoogle Scholar
  58. 58.
    Knight BP, Desai A, Coman J, Faddis M, Yong P. Long-term retention of cardiac resynchronization therapy. J Am Coll Cardiol 2004;44:7.CrossRefGoogle Scholar
  59. 59.
    Jarcho JA. Biventricular pacing. N Engl J Med 2006;355(3):288–94.PubMedCrossRefGoogle Scholar
  60. 60.
    Litwin SE, Grossman W. Diastolic dysfunction as a cause of heart failure. J Am Coll Cardiol 1993;22:49–55A.PubMedCrossRefGoogle Scholar
  61. 61.
    Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004;110(14):e340–437.PubMedGoogle Scholar
  62. 62.
    Epstein M, Lepp BA, Hoffman DS, Levinson R. Potentiation of furosemide by metolazone in refractory edema. Curr Ther Res 1977;21:656–67.Google Scholar
  63. 63.
    Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996;94:2793–9.PubMedGoogle Scholar
  64. 64.
    Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996;94:2807–16.PubMedGoogle Scholar
  65. 65.
    Miller LW. Listing criteria for cardiac transplantation: results of an American Society of Transplant Physicians–National Institutes of Health conference. Transplantation 1998;66:947–51.PubMedCrossRefGoogle Scholar
  66. 66.
    Rose EA, Moskowitz AJ, Packer M, Sollano JA, Williams DL, Tierney AR, et al. The REMATCH trial: rationale, design, and end points. Randomized evaluation of mechanical assistance for the treatment of congestive heart failure. Ann Thorac Surg 1999;67:723–30.PubMedCrossRefGoogle Scholar
  67. 67.
    Wu AH, Aaronson KD, Bolling SF, Pagani FD, Welch K, Koelling TM. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol 2005;45:381–7.PubMedCrossRefGoogle Scholar
  68. 68.
    Streeter RP, Mancini DM. Role of erythropoietin in the correction of anemia in patients with heart failure. In: Feldman, AM, editor. Heart failure: phamacologic management. Oxford: Blackwell Publishing; 2006. p. 203–14.Google Scholar
  69. 69.
    Ezekowitz JA, McAlister FA, Armstrong, PW. Anemia and its relationship to clinical outcome in heart failure. Circulation 2004;110:149–54.CrossRefGoogle Scholar
  70. 70.
    IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001;37:S182–238.Google Scholar
  71. 71.
    Jourdain P, Funck F, Gueffet P, LeHelloco H, Donal E, Aupetit JF, et al. Benefit of BNP plasma levels for optimising therapy: the systolic heart failure treatment supported by BNP multicenter randomised trial (STARS-BNP) (abstract). J Am Coll Cardiol 2005; 45:3A.Google Scholar
  72. 72.
    Felker GM, Peterson JW, Mark DB. Natriuretic peptides in the diagnosis and management of heart failure. CMAJ 175:611–7.Google Scholar
  73. 73.
    Tang WH, Girod JP, Lee MJ, Starling RC, Young JB, Van Lente F, et al. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 2003;108:2964–6.PubMedCrossRefGoogle Scholar
  74. 74.
    Committee on Quality Health Care in America, Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. Washington, DC: National Academy Press; 2001.Google Scholar
  75. 75.
    Philbin EF. Comprehensive multidisciplinary programs for the management of patients with congestive heart failure. J Gen Intern Med 1999;14:130–5.PubMedCrossRefGoogle Scholar
  76. 76.
    Whellan, DJ. Heart failure disease management: implementation and outcomes. Cardiol Rev 2005;13:231–9.PubMedCrossRefGoogle Scholar
  77. 77.
    Soumerai SB, Avorn J. Principles of educational outreach (“academic detailing”) to improve clinical decision making. JAMA 1990;263:549–56.PubMedCrossRefGoogle Scholar

Copyright information

© The American Society of Contempary Medicine and Surgery 2007

Authors and Affiliations

  • David Rosen
    • 1
  • Matthew V. Decaro
    • 2
    • 3
    • 4
  • Mark G. Graham
    • 2
    • 5
    • 6
  1. 1.Beth Israel Medical CenterNew YorkUSA
  2. 2.Jefferson Medical CollegePhiladelphiaUSA
  3. 3.Coronary Care UnitThomas Jefferson University HospitalPhiladelphiaUSA
  4. 4.Cardiology Fellowship ProgramThomas Jefferson University HospitalPhiladelphiaUSA
  5. 5.Jefferson Hospital Ambulatory PracticeThomas Jefferson University HospitalPhiladelphiaUSA
  6. 6.Internal Medicine ResidencyThomas Jefferson University HospitalPhiladelphiaUSA

Personalised recommendations